Intersection · Compounds × retatrutide

Compounds topics tagged retatrutide

Topics in Compounds carrying the tag retatrutide. Triple GIP, GLP-1 and glucagon receptor agonist; phase 3 ongoing.

21 topics

Topic	Participants	Replies	Views	Activity
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? randomised trial effect size TRIUMPH programme retatrutide Solved Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…	+43	47	5.5k	just now
What TRIUMPH is designed to answer, and why we should not pre-empt it retatrutide effect size TRIUMPH programme preprint Solved What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…	+4	8	142	6h
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+10	14	8.4k	16h
Why retatrutide discussion here is more cautious than elsewhere — one year on TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Retatrutide mass and identity: what a report should show TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h
Follow-up: The retatrutide phase 2 obesity paper, read closely retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction retatrutide preprint randomised trial effect size Solved The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…	+43	47	19k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…	+3	7	1k	2mo
Why retatrutide discussion here is more cautious than elsewhere randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
Retatrutide's phase 2 heart-rate signal and how to think about it randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
[2026 update] What we do not know about retatrutide, listed explicitly TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
Triple agonism: additive, synergistic, or neither? retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+71	80	38k	11mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper randomised trial preprint effect size retatrutide Solved Closed On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do not think it…	+12	16	50k	12mo
Second pass at: Retatrutide mass and identity: what a report should show retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
Retatrutide dose escalation in the published trials preprint retatrutide effect size Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…	+149	159	30k	15mo
What we do not know about retatrutide, listed explicitly retatrutide effect size preprint TRIUMPH programme The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024) with SURMOUNT-OSA…	+106	113	4.8k	17mo
About the Retatrutide category retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
Second pass at: Retatrutide dose escalation in the published trials retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…	+115	125	30k	2y

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →